바이오비쥬

489460KOSDAQ기타 화학제품 제조업

62.0 / 100

Reference Date: 2026-06-10

Financial Score25.0 / 40

News Sentiment20.0 / 25

Momentum5.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and ROE significantly exceeds the industry average is also solid. Declined 15.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioViju is a global export-focused company specializing in the research, development, and manufacturing of hyaluronic acid (HA)-based skin boosters and fillers, utilizing cross-linking and LNP technologies to ensure product safety. With its own production facility and ISO certification, the company is expanding OEM and general distribution, aiming to secure growth momentum through the expansion of HA filler approvals both domestically and internationally.

Number of Employees

51people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

22.11Industry Average 16.503.0Point

Higher than industry avg (caution)

PBR

1.60Industry Average 1.132.5Point

Higher than industry avg (caution)

ROE

8.94Industry Average 4.555.5Point

2.0x industry avg (good)

Debt Ratio

0.31Industry Average 8.138.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
바이오비쥬, 20억원 규모 자사주 취득 결정…“매입 후 소각”
바이오비쥬의 자기주식 취득 결정은 주주환원 강화로 이어져 주주가치 제고에 긍정적 영향을 미칠 것으로 보인다.
Positive
경과원 “중소-벤처 투자부터 ESG까지 맞춤 지원”
바이오비쥬 관련 중소기업 엘시텍의 혁신적인 기술 개발로 국내 시장 경쟁력 강화 및 투자 확대 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 6,590Won52-week high 22,45052-week low 6,210

1-month return1.0Point

1m -14.97% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0

Positive주요사항보고서(자기주식취득결정)2026-06-01
Neutral기업설명회(IR)개최2026-05-20
Neutral분기보고서 (2026.03)2026-05-14